Literature DB >> 16311601

Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity.

Jennifer E Fenner1, Robyn Starr, Ann L Cornish, Jian-Guo Zhang, Donald Metcalf, Robert D Schreiber, Kathleen Sheehan, Douglas J Hilton, Warren S Alexander, Paul J Hertzog.   

Abstract

Suppressor of cytokine signaling 1 (SOCS1) is a critical regulator of cytokine signaling and immune responses. SOCS1-deficient mice develop severe inflammatory disease, but are very resistant to viral infections. Using neutralizing antibody to type I interferon (IFN-alpha and IFN-beta) and mice deficient in interferon-gamma or type I interferon receptor components (IFNAR1 or IFNAR2), we demonstrate here that SOCS1 deficiency amplified type I interferon antiviral and proinflammatory actions independently of interferon-gamma. The mechanism of the suppression of type I interferon responses by SOCS1 was distinct from that of other cytokines. SOCS1 associated with and regulated IFNAR1- but not IFNAR2-specific signals, abrogating tyrosine phosphorylation of transcription factor STAT1 and reducing the duration of antiviral gene expression. Thus, SOCS1 is an important in vivo inhibitor of type I interferon signaling and contributes to balancing its beneficial antiviral versus detrimental proinflammatory effects on innate immunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16311601     DOI: 10.1038/ni1287

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  114 in total

Review 1.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

2.  Single cell RNA sequencing identifies an early monocyte gene signature in acute respiratory distress syndrome.

Authors:  Yale Jiang; Brian R Rosborough; Jie Chen; Sudipta Das; Georgios D Kitsios; Bryan J McVerry; Rama K Mallampalli; Janet S Lee; Anuradha Ray; Wei Chen; Prabir Ray
Journal:  JCI Insight       Date:  2020-07-09

Review 3.  Tuberculosis and HIV Coinfection.

Authors:  Judith Bruchfeld; Margarida Correia-Neves; Gunilla Källenius
Journal:  Cold Spring Harb Perspect Med       Date:  2015-02-26       Impact factor: 6.915

Review 4.  Should we inhibit type I interferons in sepsis?

Authors:  Tina Mahieu; Claude Libert
Journal:  Infect Immun       Date:  2006-09-25       Impact factor: 3.441

5.  Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2.

Authors:  Rebecca A R Piganis; Nicole A De Weerd; Jodee A Gould; Christian W Schindler; Ashley Mansell; Sandra E Nicholson; Paul J Hertzog
Journal:  J Biol Chem       Date:  2011-07-13       Impact factor: 5.157

6.  Oxymatrine Sensitizes the HaCaT Cells to the IFN-γ Pathway and Downregulates MDC, ICAM-1, and SOCS1 by Activating p38, JNK, and Akt.

Authors:  Chun-Jie Gao; Pei-Jun Ding; Li-Li Yang; Xu-Feng He; Meng-Jiao Chen; Dong-Ming Wang; Yan-Xin Tian; Hui-Min Zhang
Journal:  Inflammation       Date:  2018-03       Impact factor: 4.092

Review 7.  Interferon-stimulated genes: a complex web of host defenses.

Authors:  William M Schneider; Meike Dittmann Chevillotte; Charles M Rice
Journal:  Annu Rev Immunol       Date:  2014-02-06       Impact factor: 28.527

8.  IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus.

Authors:  Christophe Richez; Kei Yasuda; Ramon G Bonegio; Amanda A Watkins; Tamar Aprahamian; Patricia Busto; Rocco J Richards; Chih Long Liu; Regina Cheung; Paul J Utz; Ann Marshak-Rothstein; Ian R Rifkin
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

Review 9.  The Neuro-Immune-Regulators (NIREGs) Promote Tissue Resilience; a Vital Component of the Host's Defense Strategy against Neuroinflammation.

Authors:  Yosra Bedoui; Jim W Neal; Philippe Gasque
Journal:  J Neuroimmune Pharmacol       Date:  2018-06-16       Impact factor: 4.147

10.  Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors.

Authors:  Andrea Worschech; Maciej Kmieciak; Keith L Knutson; Harry D Bear; Aladar A Szalay; Ena Wang; Francesco M Marincola; Masoud H Manjili
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.